ES2197003A1 - Nuevos compuestos antagonistas de integrinas alfa. - Google Patents

Nuevos compuestos antagonistas de integrinas alfa.

Info

Publication number
ES2197003A1
ES2197003A1 ES200200805A ES200200805A ES2197003A1 ES 2197003 A1 ES2197003 A1 ES 2197003A1 ES 200200805 A ES200200805 A ES 200200805A ES 200200805 A ES200200805 A ES 200200805A ES 2197003 A1 ES2197003 A1 ES 2197003A1
Authority
ES
Spain
Prior art keywords
alpha
antagonist activity
integrin antagonist
heterocyclic amides
amides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200200805A
Other languages
English (en)
Other versions
ES2197003B1 (es
Inventor
Gonzalez Elena Carceller
Solana Jorge Salas
Farrerons Cristina Alvarez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noucor Health SA
Original Assignee
J Uriach y Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200200805A priority Critical patent/ES2197003B1/es
Application filed by J Uriach y Cia SA filed Critical J Uriach y Cia SA
Priority to PCT/EP2003/003635 priority patent/WO2003084984A1/en
Priority to KR10-2004-7015916A priority patent/KR20040094912A/ko
Priority to CA002477943A priority patent/CA2477943A1/en
Priority to JP2003582179A priority patent/JP2006506320A/ja
Priority to AU2003233958A priority patent/AU2003233958A1/en
Priority to MXPA04008990A priority patent/MXPA04008990A/es
Priority to BR0309120-1A priority patent/BR0309120A/pt
Priority to EP03727281A priority patent/EP1495044A1/en
Priority to ARP030101227A priority patent/AR039401A1/es
Priority to US10/510,626 priority patent/US20050143391A1/en
Publication of ES2197003A1 publication Critical patent/ES2197003A1/es
Priority to NO20044330A priority patent/NO20044330L/no
Application granted granted Critical
Publication of ES2197003B1 publication Critical patent/ES2197003B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Nuevos compuestos antagonistas de integrinas alfa. La presente invención se refiere a nuevos compuestos de fórmula I y sus sales, solvatos y prodrogas, en donde los significados de los distintos sustituyentes son como se indican en la parte descriptiva. Estos compuestos son útiles como antagonistas de integrinas alfa.
ES200200805A 2002-04-08 2002-04-08 Nuevos compuestos antagonistas de integrinas alfa. Expired - Fee Related ES2197003B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES200200805A ES2197003B1 (es) 2002-04-08 2002-04-08 Nuevos compuestos antagonistas de integrinas alfa.
EP03727281A EP1495044A1 (en) 2002-04-08 2003-04-08 Heterocyclic amides with alpha-4 integrin antagonist activity
CA002477943A CA2477943A1 (en) 2002-04-08 2003-04-08 Heterocyclic amides with alpha-4 integrin antagonist activity
JP2003582179A JP2006506320A (ja) 2002-04-08 2003-04-08 α４インテグリン拮抗薬活性を有する新規化合物
AU2003233958A AU2003233958A1 (en) 2002-04-08 2003-04-08 Heterocyclic amides with alpha-4 integrin antagonist activity
MXPA04008990A MXPA04008990A (es) 2002-04-08 2003-04-08 Amidas heterociclicas con actividad antagonista de (4 integrinas.
PCT/EP2003/003635 WO2003084984A1 (en) 2002-04-08 2003-04-08 Heterocyclic amides with alpha-4 integrin antagonist activity
KR10-2004-7015916A KR20040094912A (ko) 2002-04-08 2003-04-08 알파-4 인테그린 안타고니스트 활성을 갖는 헤테로시클릭아미드
ARP030101227A AR039401A1 (es) 2002-04-08 2003-04-08 Un compuesto antagonista de integrinas alfa 4 y un procedimiento para preparar el mismo
US10/510,626 US20050143391A1 (en) 2002-04-08 2003-04-08 Heterocyclic amides with alpha-4 integrin antagonist activity
BR0309120-1A BR0309120A (pt) 2002-04-08 2003-04-08 Compostos com atividade antagonista de integrina alfa4
NO20044330A NO20044330L (no) 2002-04-08 2004-10-12 Heterosykliske amider med alfa-4 intergrin-antagonistaktivitet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200200805A ES2197003B1 (es) 2002-04-08 2002-04-08 Nuevos compuestos antagonistas de integrinas alfa.

Publications (2)

Publication Number Publication Date
ES2197003A1 true ES2197003A1 (es) 2003-12-16
ES2197003B1 ES2197003B1 (es) 2005-03-16

Family

ID=28686084

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200200805A Expired - Fee Related ES2197003B1 (es) 2002-04-08 2002-04-08 Nuevos compuestos antagonistas de integrinas alfa.

Country Status (12)

Country Link
US (1) US20050143391A1 (es)
EP (1) EP1495044A1 (es)
JP (1) JP2006506320A (es)
KR (1) KR20040094912A (es)
AR (1) AR039401A1 (es)
AU (1) AU2003233958A1 (es)
BR (1) BR0309120A (es)
CA (1) CA2477943A1 (es)
ES (1) ES2197003B1 (es)
MX (1) MXPA04008990A (es)
NO (1) NO20044330L (es)
WO (1) WO2003084984A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005265316B2 (en) * 2004-07-08 2012-02-02 Elan Pharmaceuticals, Inc. Multivalent VLA-4 antagonists comprising polymer moieties
US20080312281A1 (en) * 2004-12-24 2008-12-18 Matthew Colin Thor Fyfe G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes
NZ563577A (en) 2005-05-20 2011-04-29 Elan Pharm Inc Imidazolone phenylalanine derivatives as VLA-4 antagonists
US8987306B2 (en) 2005-06-07 2015-03-24 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
US8258159B2 (en) * 2005-06-07 2012-09-04 The Trustees Of The University Of Pennsylvania Inhibitors of the α2β1/GPIa-IIa integrin
EP1909791A1 (en) * 2005-06-30 2008-04-16 Prosidion Limited G-protein coupled receptor agonists
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
ATE546441T1 (de) 2007-12-05 2012-03-15 Astrazeneca Ab Piperazinderivate und ihre verwendung als modulatoren des leptinrezeptors
WO2009071658A1 (en) * 2007-12-05 2009-06-11 Biovitrum Ab (Publ) Piperazines as anti-obesity agents
KR20100097701A (ko) * 2007-12-05 2010-09-03 아스트라제네카 아베 비만 치료제로서의 모르폴린 유도체
WO2009124037A1 (en) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
CA2769473A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
US10836720B2 (en) 2016-04-01 2020-11-17 The Regents Of The University Of California Inhibitors of integrin alpha 5 beta 1 and methods of use
WO2018085552A1 (en) * 2016-11-02 2018-05-11 Saint Louis University Integrin antagonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006432A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4
WO2001012186A1 (en) * 1999-08-13 2001-02-22 Biogen, Inc. Cell adhesion inhibitors
WO2001054690A1 (en) * 2000-01-28 2001-08-02 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053814A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006432A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4
WO2001012186A1 (en) * 1999-08-13 2001-02-22 Biogen, Inc. Cell adhesion inhibitors
WO2001054690A1 (en) * 2000-01-28 2001-08-02 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses

Also Published As

Publication number Publication date
NO20044330L (no) 2004-10-28
KR20040094912A (ko) 2004-11-10
WO2003084984A1 (en) 2003-10-16
BR0309120A (pt) 2005-01-11
MXPA04008990A (es) 2005-06-20
JP2006506320A (ja) 2006-02-23
EP1495044A1 (en) 2005-01-12
CA2477943A1 (en) 2003-10-16
AU2003233958A1 (en) 2003-10-20
AR039401A1 (es) 2005-02-16
US20050143391A1 (en) 2005-06-30
WO2003084984A8 (en) 2003-12-11
ES2197003B1 (es) 2005-03-16

Similar Documents

Publication Publication Date Title
ES2197003A1 (es) Nuevos compuestos antagonistas de integrinas alfa.
TW200504061A (en) Pyrazolopyridine derivatives
TW200618800A (en) Heterocyclic compounds
RS92004A (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
TW200608977A (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
PL373645A1 (en) Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
EA200500017A1 (ru) Новые соединения
ATE453639T1 (de) Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer
IL155875A0 (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
TNSN07272A1 (en) Substituted bis aryl and heteroaryl compounds as selective 5ht 2a antagonists
MX2007007098A (es) Derivados de pirrol que tienen actividad antagonista del receptor crth2.
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
ATE325796T1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
TW200734313A (en) Piperazines and piperidines as mGluR5 potentiators
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
TW200626145A (en) Heterocyclic compounds and thrombopoietin receptor activators
TW200512201A (en) New heterocyclic amides
RS20060072A (en) Aminoquinoline derivatives and their use as adenosine a3 ligands
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
MXPA05010651A (es) Compuestos de pirazol.
RS20050506A (en) Novel herbicides
MXPA05009282A (es) Derivados de anilina sustituidos.
ATE517623T1 (de) Verwendung von methylphenidat-derivaten
TW200606153A (en) Process for producing pyridine derivatives of Nk-1 receptor antagonist

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031216

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2197003B1

Country of ref document: ES

FD1A Patent lapsed

Effective date: 20100312